|
|
|
"
About the Novartis Vaccines global meningococcal franchise
Menveo is based on the same proprietary technology Novartis Vaccines pioneered to produce Menjugate, a meningococcal serogroup C conjugate vaccine approved outside the US since 2000 for use in individuals from age 2 months through adulthood. There is no vaccine currently licensed in the US for use in infants. In the US, the prevalence of serogroup Y has increased over the last few years (from 9% of reported cases in 1990-92 to 39% in 2006)[3]. The dynamic and unpredictable nature of meningococcal disease epidemiology warrants a vaccine that offers broad serogroup protection[6]. In particular, management's expectations regarding Menveo could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including an unexpected inability to meet the requirements of the FDA: unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world.
AEOL 10150 offers several unique advantages as a countermeasure for the treatment of ARS, mustard gas and chlorine gas for civilian and military populations.
buy xanax on perscritpion buy xanax online pharmacy racecar xanax bob xanax as tranquilizer i can't sleep xanax date first on market xanax detox rehabilitation xanax for treatment of performance anxiety xanax in college xanax originations
There is no vaccine currently licensed in the US for use in infants.
Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease.
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. 2008;299(2): 173-184 [2. “We have now seen the drug protect in both mice and in rats, and it has protected multiple organ systems in the body. McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc. A compound with the potential to protect against multiple threats would be of significant benefit in both the military and civilian efforts to protect citizens against potential threats.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005